Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Published byMyles Todd Douglas Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM."— Presentation transcript:

1 Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by week (B), and the proportion of CSBM responders by week (C) in COMPOSE-4 (proportion ± 95% CI; FAS). *P <  versus placebo. CI, confidence interval; CSBM, complete spontaneous bowel movement; FAS, full analysis set; SBM, spontaneous bowel movement. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. Proportion of subjects with ≥ 1 SBM (A) or ≥ 1 CSBM (B) at specific time points within 24 h after the initial ... Figure 2. Proportion of subjects with ≥ 1 SBM (A) or ≥ 1 CSBM (B) at specific time points within 24 h after the initial dose of the study drug in COMPOSE-4 (proportion ± 95% CI; FAS). *P <  versus placebo. CI, confidence interval; CSBM, complete spontaneous bowel movement; FAS, full analysis set; SBM, spontaneous bowel movement. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3. Kaplan–Meier curve of time to first SBM (A) or CSBM (B) in COMPOSE-4 (FAS). Circles represent censored time. ... Figure 3. Kaplan–Meier curve of time to first SBM (A) or CSBM (B) in COMPOSE-4 (FAS). Circles represent censored time. The time to the first SBM or CSBM was censored for subjects who withdrew from the study before an SBM or CSBM was observed, or if no SBM or CSBM occurred during the 2-week treatment period. CSBM, complete spontaneous bowel movement; FAS, full analysis set; SBM, spontaneous bowel movement. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4. Change from baseline to day 15 of COMPOSE-4 in PAC-SYM (A) and PAC-QOL (B) overall scores and scores for each ... Figure 4. Change from baseline to day 15 of COMPOSE-4 in PAC-SYM (A) and PAC-QOL (B) overall scores and scores for each domain [mean (SD); FAS]. *P = 0.045 versus placebo. <sup>†</sup>P = 0.015 versus placebo. FAS, full analysis set; ns, not significant; PAC-QOL, Patient Assessment of Constipation Quality of Life; PAC-SYM, Patient Assessment of Constipation Symptoms; SD, standard deviation. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, The content of this slide may be subject to copyright: please see the slide notes for details.

5 Figure 5. Change from baseline (predose on day 1 of COMPOSE-4) over time in PAC-SYM (A) and PAC-QOL (B) overall scores ... Figure 5. Change from baseline (predose on day 1 of COMPOSE-4) over time in PAC-SYM (A) and PAC-QOL (B) overall scores and scores for each domain in COMPOSE-5 (mean; FAS). *P ≤ 0.03 versus BL for mean overall scores and scores for each domain of PAC-SYM. <sup>†</sup>P ≤  versus BL for mean overall scores and scores for each domain of PAC-QOL. BL, baseline; FAS, full analysis set; PAC-QOL, Patient Assessment of Constipation Quality of Life; PAC-SYM, Patient Assessment of Constipation Symptoms. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Ann Oncol, Volume 29, Issue 6, 18 April 2018, Pages 1461–1467, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM."

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ±

FIGURE 4: Mean change from baseline in iPTH concentration during treatment and 60 days after treatment withdrawal. Data are shown as the mean change ±
Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.

Figure 1 Proportion of criteria chosen (as percentages, grouped into issues). From: Developing national obesity policy in middle-income countries: a case.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion
Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Similar presentations

Ads by Google